Previous Winners

Winner: Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Yamazaki CM, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J, Ueno NT, Zhang N, An Z, Tsuchikama K. Nat Commun. 2021 Jun 10;12(1):3528. doi: 10.1038/s41467-021-23793-7. PMID: 34112795

Runner-Up: The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. Kendsersky NM, Lindsay J, Kolb EA, Smith MA, Teicher BA, Erickson SW, Earley EJ, Mosse YP, Martinez D, Pogoriler J, Krytska K, Patel K, Groff D, Tsang M, Ghilu S, Wang Y, Seaman S, Feng Y, Croix BS, Gorlick R, Kurmasheva R, Houghton PJ, Maris JM. Clin Cancer Res. 2021 May 15;27(10):2938-2946. doi: 10.1158/1078-0432.CCR-20-4221. Epub 2021 Feb 22. PMID: 33619171

Best ADC Clinical Publication 2021

Winner: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. PMID: 33882206 Clinical Trial.

Runner-Up: Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C.Lancet Oncol. 2021 Jun;22(6):790-800. doi: 10.1016/S1470-2045(21)00139-X. Epub 2021 May 11. PMID: 33989558 Clinical Trial.

Outstanding Academic Investigator

The George R. Pettit Individual Input to the Field 2021

Long Standing Contribution to the Field

2021 - 8th World ADC Awards

Best ADC Platform Technology

Best Contract Research (CRO) Provider

Best Contract Manufacturing (CMO) Provider

Best New Drug Developer

Most Promising Clinical Candidate

Best Poster 2022

Best ADC Pre-Clinical Publication 2021

Winner: A bi-orthogonal system reveals antitumour immune function of pyroptosis.

Pyrop-tyosis

Wang Q, Wang Y, Ding J, Wang C, Zhou X, Gao W, Huang H, Shao F, Liu Z.Nature. 2020 Mar;579(7799):421-426. doi: 10.1038/s41586-020-2079-1. Epub 2020 Mar 11.PMID: 32188939

Citations: 106

Runner Up: Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.

Maneiro MA, Forte N, Shchepinova MM, Kounde CS, Chudasama V, Baker JR, Tate EW.ACS Chem Biol. 2020 Jun 19;15(6):1306-1312. doi: 10.1021/acschembio.0c00285. Epub 2020 Apr 30.PMID: 32338867

Citations: 30

Best ADC Clinical Publication 2021

Winner: Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators.N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.PMID: 31825192

Citations: 456

Runner Up: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ.J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6.PMID: 31693429

Citations: 206

Outstanding Academic Investigator

The George R. Pettit Individual Input to the Field 2020

Long Standing Contribution to the Field

2020 - 7th World ADC Awards

Best ADC Platform Technology

Best Contract Research (CRO) Provider

Best Contract Manufacturing (CMO) Provider

Best New Drug Developer

Most Promising Clinical Candidate

Best ADC Pre-Clinical Publication 2019

Winner:
Czechowicz A, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Pang WW, Mansour MK, Tate TA, Chan YY, Walck E, Wernig G, Shizuru JA, Winau F, Scadden DT, Rossi DJ. Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. Nat Commun. 2019 Feb 6;10(1):617. doi: 10.1038/s41467-018-08201-x. PMID: 30728354; PMCID: PMC6365495.

Runner Up:
Yamada K, Shikida N, Shimbo K, Ito Y, Khedri Z, Matsuda Y, Mendelsohn BA. AJICAP: Affinity Peptide Mediated Regiodivergent Functionalization of Native Antibodies. Angew Chem Int Ed Engl. 2019 Apr 16;58(17):5592-5597. doi: 10.1002/anie.201814215. Epub 2019 Mar 29. PMID: 30854738

Best ADC Clinical Publication 2019

Winner:
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. PMID: 30516102.

Individual Input to the Field 2019

Long Standing Contribution to the Field

2019 - 6th World ADC Awards

Best ADC Platform Technology

Best Contract Research (CRO) Provider

Best Contract Manufacturing (CMO) Provider

Best New Drug Developer

Most Promising Clinical Candidate

Best Poster 2019

Best ADC Pre-Clinical Publication

Winner:
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice. Rossin R, Versteegen RM, Wu J, Khasanov A, Wessels HJ, Steenbergen EJ, Ten Hoeve W, Janssen HM, van Onzen AHAM, Hudson PJ, Robillard MS. Nat Commun. 2018 May 4;9(1):1484.

Runner Up:
Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis. Cazzamalli S, Dal Corso A, Widmayer F, Neri D. J Am Chem Soc. 2018 Feb 7;140(5):1617-1621.

Best ADC Clinical Publication

Winner:
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984.

Individual Input to the Field 2018

Long Standing Contribution to the Field

2018 - 5th World ADC Awards

Best ADC Platform Technology

Best Contract Research (CRO) Provider

Best Contract Manufacturing (CMO) Provider

Best New Drug Developer

Most Promising Clinical Candidate

Best ADC Publication

Winner: Rovalpituzumab tesirine, a DLL3-targeted antibody-drugconjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCRX16-001 investigators. Lancet Oncol. 2017 Jan;18(1):42-51.

Runner Up: Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. J Clin Oncol. 2017 Jan 10;35(2):141-148.

Individual Input to the Field

Long Standing Contribution to the Field

Older Awards

2017 - 4th World ADC Awards

Best ADC Platform Technology
Winner - Bicycle Therapeutics
Runner-Up -SynAffix
Most Promising Clinical Candidate
Winner - Immunogen (Mirvetuximab soravtansine)
Runner-Up - Stemcentrx (Rova-T)
Best Contract Manufacturing (CMO) Provider
Winner - Lonza
Runner-up - BSP Pharmaceuticals
Best New Drug Developer
Winner - Mersana Therapeutics
Runner-Up - Heidelberg Pharma
Best Contract Research (CRO) Provider
Winner - PPD
Runner-Up - SynGene
Best Publication 2016
Winner - A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy (Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJ, et al.).
Individual Input to the Field:
Winner - Gregory Winter
Long-Standing Contribution:
Winner - Jagath Reddy Junutula

2016 - 3rd World ADC Awards

Best ADC Platform Technology
Winner – Fleximer (Mersana Therapeutics)
Runner Up – Bicycles (Bicycle Therapeutics)
Most Promising Clinical Candidate
Winner – Rovalpituzumab tesirine (Abbvie-Stemcentrx)
Runner Up – MEDI4276 (MedImmune)
Best Contract Manufacturing (CMO) Provider
Winner - BSP Pharmaceuticals
Runner Up - Piramal
Best Contract Research (CRO) Provider
Winner - Abzena
Best New Drug Developer sponsored by Pfizer
Winner - ADC Therapeutics
Runner Up – Mersana Therapeutics
Best Publication 2015
Winner - Saunders et al., A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med., 2015.
Best Poster sponsored by Abbvie
Winner - Computational Exploration of Mechanistic Determinants of ADC Pharmacokinetics Using QSP Modeling Strategies; AK Wilkens et al.
Runner Up - Discovery and Characterization of ADCs with a Novel Mode of Action; G Piizzi et al.
Individual Input to the Field 2015/2016
Winner - David Thurston
Runner Up - Scott Dylla
Long-Standing Contribution
Winner - John Lambert

2015 - 2nd World ADC Awards

Best ADC Platform Technology
Winner – Genentech (THIOMAB)
Runner Up – Sutro Biopharma (nnAA)
Best New Drug Developer
Winner – Stemcentrx
Runner Up – ADC Therapeutics
Most Promising Clinical Candidate
Winner – Seattle Genetics (SGN-CD33A)
Runner Up – Immunomedics (Sacituzumab Govitecan)
Best Contract Service Provider
Winner – BSP Pharmaceuticals (CMO)
Runner Up – Piramal (CMO)
Best Publication 2010-2014
Winner - Shen et al. Conjugation site modulates the in vivostability and therapeutic activity of antibody-drug conjugates
Nature Biotech 2012
Individual Input to the Field 2014/2015
Winner – Hans Peter Gerber (Pfizer)
Runner Up – Patrick van Berkel (ADC Therapeutics)

2014 - 1st World ADC Awards

Most Promising Drug Candidate
Winner: IMGN289 (ImmunoGen)
Runner Up: Polatuzumab Vedotin (Genentech)
Best Scientific Innovation
Winner: PBD (Spirogen)
Runner Up: None
Best Contract Service Provider
Winner: Piramal
Runner up: Lonz
Best Team:
Winner: Lonza Bioconjugates Team
Runner Up: ImmunoGen Scientific Leadership
Runner Up: Peter Senter’s Chemistry Group
Individual Input to Field (2013/2014):
Winner: Chris Martin
Runner up: John Lambert
Long-Standing Contribution to the Field:
Winner: Peter Senter
Runner Up: Ravi Chari

Explore World ADC San Diego's Agenda

Discover the latest industry breakthroughs and insights to be shared at the biggest ADC event, ahead of the awards' gala.

View the Full Event Guide

Partner With Us

Position yourself in front of the pioneers trailblazing ADCs to standard of care treatments.

Explore Sponsorship Options

Submit Your Nominations

Have your say on who gets recognized this year because of their exceptional work propelling the ADC field to new heights.

Vote Now

Previous Winners

Discover All Our Winners Throughout the Years

2023 - 10th World ADC Awards

2022 - 9th World ADC Awards

2021 - 8th World ADC Awards

2020 - 7th World ADC Awards

2019 - 6th World ADC Awards

2018 - 5th World ADC Awards

Older Awards

Explore World ADC San Diego's Agenda

Partner With Us

Submit Your Nominations

Venue

Map

Contact

Join Our Team

About Us

Explore Our Products

Stay Connected

Search

Organized By